Chafic Karam1, Louis A Tramontozzi1. 1. ALS and Neuromuscular Disease Center (CK), Oregon Health and Science University, Portland; Department of Neurology (CK), the University of North Carolina, Chapel Hill; Rapid screening for inflammatory neuropathies by standardized clinical criteria; and North Shore Neurology & EMG (LAT), LLC, Beverly, MA.
Abstract
BACKGROUND: Delay in recognition and treatment of inflammatory neuropathies increases morbidity and mortality. We have developed and standardized 3 clinical screening criteria that rapidly detect inflammatory neuropathies. METHODS: We reviewed all patients with definite large fiber neuropathy in 2 different patient populations: 1 from a private neurology clinic and the other from a tertiary care center. Patients were divided into 2 groups: those with an inflammatory neuropathy and those with a noninflammatory neuropathy. We specifically noted the 3 key neuropathy characteristics: onset, distribution, and associated systemic features (ODS). We studied the sensitivity and specificity of ODS in differentiating between inflammatory and noninflammatory neuropathies. RESULTS: A total of 206 patients were included: 51 from the private clinic and 155 from the tertiary care center. The sensitivity of using ODS in detecting an inflammatory neuropathy was 96% and the specificity was 85%. The positive predictive value of ODS was 0.8 and negative predictive value was 0.97. CONCLUSIONS: Rapid screening for inflammatory neuropathies by ODS clinical criteria is highly sensitive and has a high negative predictive value for noninflammatory neuropathies. ODS uses simple clinical criteria to rapidly screen for patients with a potentially treatable form of neuropathy and accelerate their diagnostic evaluation. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that 3 neuropathy characteristics-onset, distribution, and associated systemic features-accurately identify patients with inflammatory neuropathies.
BACKGROUND: Delay in recognition and treatment of inflammatory neuropathies increases morbidity and mortality. We have developed and standardized 3 clinical screening criteria that rapidly detect inflammatory neuropathies. METHODS: We reviewed all patients with definite large fiber neuropathy in 2 different patient populations: 1 from a private neurology clinic and the other from a tertiary care center. Patients were divided into 2 groups: those with an inflammatory neuropathy and those with a noninflammatory neuropathy. We specifically noted the 3 key neuropathy characteristics: onset, distribution, and associated systemic features (ODS). We studied the sensitivity and specificity of ODS in differentiating between inflammatory and noninflammatory neuropathies. RESULTS: A total of 206 patients were included: 51 from the private clinic and 155 from the tertiary care center. The sensitivity of using ODS in detecting an inflammatory neuropathy was 96% and the specificity was 85%. The positive predictive value of ODS was 0.8 and negative predictive value was 0.97. CONCLUSIONS: Rapid screening for inflammatory neuropathies by ODS clinical criteria is highly sensitive and has a high negative predictive value for noninflammatory neuropathies. ODS uses simple clinical criteria to rapidly screen for patients with a potentially treatable form of neuropathy and accelerate their diagnostic evaluation. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that 3 neuropathy characteristics-onset, distribution, and associated systemic features-accurately identify patients with inflammatory neuropathies.
Authors: Brian C Callaghan; James F Burke; Ann Rodgers; Ryan McCammon; Kenneth M Langa; Eva L Feldman; Kevin A Kerber Journal: Neurol Clin Pract Date: 2013-10
Authors: Brian C Callaghan; Kevin A Kerber; Mousumi Banerjee; Eva L Feldman; Lewis B Morgenstern; Ruth Longoria; Ann Rodgers; Paxton Longwell; Lynda D Lisabeth Journal: J Neurol Neurosurg Psychiatry Date: 2015-01-20 Impact factor: 10.154
Authors: Mamatha Pasnoor; Osvaldo J M Nascimento; Jaya Trivedi; Gil I Wolfe; Sharon Nations; Laura Herbelin; M G de Freitas; Giseli Quintanilha; Saud Khan; Mazen Dimachkie; Richard Barohn Journal: Int J Neurosci Date: 2013-04-17 Impact factor: 2.292